Ireland-headquartered rare disease specialist Shire (LSE: SHP) has entered into a collaboration to exclusively conduct research on the use of the Rani Pill technology for the oral delivery of factor VIII (FVIII) therapy for patients with hemophilia A, developed by Rani Therapeutics, a spin-out from InCube Labs.
Under the terms of the deal, Shire gains an exclusive option to negotiate a license to develop and commercialize the technology for delivery of FVIII therapy following completion of feasibility studies. As part of the collaboration, Shire has also made an equity investment into Rani Therapeutics. The specific terms of this deal were not disclosed.
Shares in Shire were down 1.0% at 3,609.50 pence Tuesday after the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze